Hirokazu Taniguchi

Senior Assistant Professor

Nagasaki University Hospital
Country flagJapan
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

Pleural mesothelioma (PM) is a rare and aggressive malignancy. The development of novel therapeutic strategies targeting PM remains an unmet clinical need. However, comprehensive genomic data from Asian populations, particularly from Japanese patients, are limited. This study aimed to elucidate the genomic landscape of PM in Japanese patients using the nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) genomic database. A total of 211 patients registered between June 2019 and March 2025 were analyzed. The most frequent genetic alterations were in BAP1, NF2, TP53, CDKN2A/B, and MTAP. The median tumor mutation burden (TMB) was 1.26, and no microsatellite instability–high patients were detected. The median overall survival (OS) after first-line treatment was 30.6 months. Patients treated with immune checkpoint inhibitors (ICIs) had a significantly better OS than those who did not receive ICIs. In univariate and multivariate analyses, TP53 alterations and high TMB (cutoff value of 1.6) were associated with poor prognosis. These results suggest that integrating clinical and genomic data can enhance prognostic stratification and contribute to the development of precision medicine for PM. This study provides the first large-scale genomic characterization of Japanese PM patients with C-CAT and highlights potential biomarkers for future therapeutic development.

Year:

2026

OS and PFS of patients with or without liver metastases or history of ATB therapy in the ICI plus chemotherapy group. The Kaplan–Meier curves provide estimates of OS ( A and C ) and PFS ( B and D ) of the ICI plus chemotherapy group, stratified by patients with or without liver metastases ( A and B ) or history of ATB ( C and D ). ICI–Chemo, ICI plus chemotherapy; LM, liver metastases.

Year:

2025

Treatment outcomes according to history of ATB therapy. The Kaplan–Meier curves provide estimates of OS ( A ) and PFS ( B ) of the patients with a history of ATB therapy stratified by treatment with ICI plus chemotherapy and chemotherapy ( n = 74). OS ( C ) and PFS ( D ) of the patients without a history of ATB therapy stratified by treatment with ICI plus chemotherapy and chemotherapy ( n = 472). Chemo, chemotherapy; ICI–Chemo, ICI plus chemotherapy.

Year:

2025

Treatment outcomes according to liver metastases. The Kaplan–Meier curves provide estimates of OS ( A ) and PFS ( B ) of the patients with liver metastases stratified by treatment with ICI plus chemotherapy and chemotherapy ( n = 76). OS ( C ) and PFS ( D ) of the patients without liver metastases (non-LM) stratified by treatment with ICI plus chemotherapy and chemotherapy ( n = 468). Chemo, chemotherapy; ICI–Chemo, ICI plus chemotherapy; LM, liver metastases.

Year:

2025

Treatment outcomes adjusted by PSM in all patients. The Kaplan–Meier curves provide estimates of OS ( A ) and PFS ( B ) of the 550 patients stratified by treatment with ICI plus chemotherapy (ICI–Chemo) and platinum-based chemotherapy (Chemo).

Year:

2025

Chemoimmunotherapy is recommended for patients with non–small cell lung cancer (NSCLC) with low PD-L1 expression, but the effect of additional immunotherapy is heterogeneous in this population. To identify patients who do not benefit from the addition of immune checkpoint inhibitors (ICI) to chemotherapy, we conducted a retrospective study at 19 institutions in Japan. We analyzed 851 patients with advanced NSCLC with a PD-L1 tumor proportion score of 1% to 49% who received chemoimmunotherapy ( n = 504) or chemotherapy ( n = 347) between March 2017 and June 2022. After adjustment by propensity score matching, the median overall survival (OS) was 22.3 months in the chemoimmunotherapy group and 17.0 months in the chemotherapy-alone group ( P = 0.01). Multivariate analysis showed that among 12 clinical factors, liver metastases ( P = 0.001) and history of antibiotic use ( P = 0.02) were independently associated with shorter OS in the chemoimmunotherapy group. Patients with liver metastases (OS, P = 0.4; progression-free survival, P = 0.06) or history of antimicrobial use (OS, P = 0.24; progression-free survival, P = 0.09) did not benefit from the addition of ICI to chemotherapy. Patients with a history of antimicrobial use experienced more severe pneumonitis with chemoimmunotherapy than all patients ( P = 0.04). This cohort study showed that liver metastases and prior antimicrobial therapy are the most important clinical factors that attenuate the efficacy of chemoimmunotherapy in patients with low PD-L1 expression. Significance: This study shows that liver metastases and prior antibiotic use are key factors for chemoimmunotherapy in advanced NSCLC cases with low PD-L1 expression. They reduce the benefit of adding ICIs to chemotherapy, underscoring the need for new strategies to improve ICI efficacy in patients.

Year:

2025

Purpose: This study was performed to confirm the superiority in overall survival (OS) of EGFR tyrosine kinase inhibitor (TKI gefitinib or osimertinib) monotherapy versus EGFR TKI with intercalation of cisplatin plus pemetrexed as the first-line treatment for patients with advanced non-squamous non–small cell lung cancer (NSqNSCLC) harboring EGFR mutation. Patients and Methods: This was an open-label, multicenter, randomized phase III study. Patients with chemotherapy-naïve advanced or recurrent NSqNSCLC harboring EGFR mutation (exon 19 deletion or exon 21 L858R point mutation) were randomly assigned (1:1) to EGFR-TKI monotherapy or the EGFR TKI plus intercalated chemotherapy group. The primary endpoint was OS, and the secondary endpoints included progression-free survival (PFS). Results: From December 2015 to October 2020, 501 patients were randomized. The EGFR TKI was changed from gefitinib to osimertinib in October 2018 (gefitinib cohort: n = 308 and osimertinib cohort: n = 193). There was no survival advantage in the EGFR TKI plus intercalated chemotherapy group; the median survival time of both groups was 48.0 months (HR, 0.985; 91.4% confidence interval, 0.796–1.219; one-sided P = 0.4496). The median PFS time was 12.0 months in the EGFR-TKI monotherapy group and 18.0 months in the EGFR TKI plus intercalated chemotherapy group (HR, 0.762; 95% confidence interval, 0.628–0.925; one-sided P = 0.003). The OS and PFS trends in both gefitinib and osimertinib cohorts were identical to those in the entire population. Conclusions: The intercalation of cisplatin plus pemetrexed after the response to EGFR TKI improved PFS but not OS compared with EGFR TKI monotherapy as the first-line treatment for patients with advanced NSqNSCLC harboring EGFR mutation.

Year:

2025

Supplementary Figure S3. Subgroup analyses of overall survival. (A) Gefitinib cohort. (B) Osimertinib cohort. Abbreviations: CI, confidence interval; EGFR, epidermal growth factor receptor; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; ECOG, Eastern Clinical Oncology group; PS, performance status; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; CNS, central nervous system.

Year:

2025

Kaplan–Meier analysis of OS. A, ITT population. The 1-, 2-, 3-, 4-, and 5-year survival rates were 92.8%, 80.4%, 63.5%, 49.6%, and 36.9% in the control group and 94.4%, 81.7%, 69.9%, 49.9%, and 35.3% in the experimental group, respectively. B, Gefitinib cohort. The 1-, 2-, 3-, 4-, and 5-year survival rates were 91.5%, 78.4%, 59.5%, 46.3%, and 34.4% in the control group and 92.2%, 77.7%, 66.4%, 46.5%, and 32.9% in the experimental group, respectively. C, Osimertinib cohort. The 1-, 2-, and 3-year survival rates were 94.8%, 83.4%, and 69.8% in the control group and 97.9%, 88.3%, and 76.0% in the experimental group, respectively. D, Subgroup analysis of OS. ECOG, Eastern Clinical Oncology Group; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; NE; not estimable; PS, performance status.

Year:

2025

Kaplan–Meier analysis of PFS. A, ITT population. The 1-, 2-, 3-, 4-, and 5-year PFS rates were 49.2%, 26.0%, 18.0%, 12.9%, and 7.8% in the control group and 67.0%, 39.8%, 24.1%, 11.9%, and 9.5% in the experimental group, respectively. B, Gefitinib cohort. The 1-, 2-, 3-, 4-, and 5-year PFS rates were 37.3%, 13.7%, 8.5%, 6.5%, and 4.0% in the control group and 59.5%, 32.7%, 15.7%, 7.2%, and 5.7% in the experimental group, respectively. C, Osimertinib cohort. The 1-, 2-, and 3-year PFS rates were 68.0%, 45.3%, and 32.2% in the control group and 79.0%, 51.4%, and 39.6% in the experimental group, respectively. D, Subgroup analysis of PFS. ECOG, Eastern Clinical Oncology Group; Ex19del, EGFR exon 19 deletion; L858R, EGFR exon 21 L858 point mutation; PS, performance status.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (16)

Shintaro Kanda

Professor

Shinshu University

JAPAN
View details

Akihiro Yoshimura

Medical doctor

Kyoto Prefectural University of Medicine

JAPAN
View details

Charles Rudin

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Midori Matsuo

Nagasaki University

JAPAN
View details

Satoshi Watanabe

Niigata University

JAPAN
View details

Takayasu Kurata

-

JAPAN
View details

Yutaka Fujiwara

Head

Aichi Cancer Center

JAPAN
View details

Shogo Nomura

Associate Professor

University of Tokyo

JAPAN
View details

Tatsuki Ikoma

Kobe University Hospital

JAPAN
View details

Eiji Iwama

Kyushu University

JAPAN
View details

Naoki Furuya

Ohio State University

UNITED STATES
View details

Daiki Murata

Assistant Professor

Kindai University

JAPAN
View details

kyoichi kaira

Saitama Medical University

JAPAN
View details

Koichi Takayama

Professor

Kyoto Prefectural University of Medicine

JAPAN
View details

Koichi Azuma

Kurume University School of Medicine

JAPAN
View details

Seiji Niho

-

JAPAN
View details